Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Heparin sodium
Drug ID BADD_D01061
Description Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Indications and Usage Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin therapy in patients with unstable angina and/or non-Q wave myocardial infarctions (i.e. non-ST elevated acute coronary artery syndrome) who are on platelet glycoprotein (IIb/IIIa) receptor inhibitors. Additionally, it is used to prevent clotting during dialysis and surgical procedures, maintain the patency of intravenous injection devices and prevent in vitro coagulation of blood transfusions and in blood samples drawn for laboratory values.
Marketing Status approved; investigational
ATC Code B01AB01; C05BA03; S01XA14
DrugBank ID DB01109
KEGG ID D02112
MeSH ID D006493
PubChem ID 92044406
TTD Drug ID D0UX6Z
NDC Product Code 0641-2460; 53484-001; 51662-1486; 0338-0428; 63739-953; 65219-066; 67457-373; 67457-374; 0409-2723; 0409-3150; 71288-405; 71288-421; 81952-115; 44055-001; 46655-1224; 51662-1434; 55154-6985; 0338-0433; 63323-522; 63739-942; 68083-136; 71288-420; 72572-255; 0641-0410; 0641-2450; 81952-111; 57262-300; 67957-0002; 55154-9585; 63323-262; 63323-459; 63323-519; 63323-543; 63739-901; 66298-5197; 67457-383; 0404-9979; 0409-2721; 0409-4520; 0409-7651; 0409-7793; 71288-404; 71839-117; 63323-540; 63739-920; 0409-7620; 0641-0391; 0641-6199; 81565-203; 81952-114; 43796-100; 60870-0249; 67957-0001; 76392-101; 51662-1409; 51662-1411; 63323-118; 63323-542; 0409-1005; 0409-1316; 71288-422; 71288-423; 71288-424; 71839-118; 76045-108; 81952-112; 81952-116; 0069-0043; 0069-0059; 57262-370; 25021-403; 63323-047; 63323-276; 63739-986; 0404-9872; 67457-384; 0409-2222; 0409-2720; 71288-400; 71288-401; 71288-403; 72572-250; 0069-0058; 0069-0137; 42455-001; 76392-501; 25021-400; 0264-5705; 55154-5130; 55154-8138; 0409-7650; 31387-100; 57262-378; 52584-402; 55154-2380; 55154-2827; 0338-0431; 63739-931; 63739-964; 66298-5191; 67457-372; 0409-1402; 25021-404; 52584-111; 55154-8131; 55154-9583; 0338-0424; 63323-915; 63739-975; 67457-385; 67457-603; 0409-0012; 71288-419; 0641-0400; 0641-6204; 81952-113; 28955-001; 44498-002; 51552-1595; 52221-101; 52221-123; 82051-003; 25021-402; 51662-1460; 63323-517; 63323-518; 63323-523; 63739-900; 67457-602; 71288-402; 71288-406; 71288-425; 51927-0285; 25021-401
UNII ZZ45AB24CA
Synonyms Heparin | Unfractionated Heparin | Heparin, Unfractionated | Heparinic Acid | Liquaemin | Sodium Heparin | Heparin, Sodium | Heparin Sodium | alpha-Heparin | alpha Heparin
Chemical Information
Molecular Formula C26H42N2NaO37S5+
CAS Registry Number 9041-08-1
SMILES CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C( C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O.[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Adrenal haemorrhage05.01.03.002; 12.01.17.003; 24.07.01.023---
Alanine aminotransferase13.03.04.002---
Alanine aminotransferase increased13.03.04.005--
Alopecia23.02.02.001--
Anaphylactoid reaction10.01.07.003; 24.06.03.007---
Aspartate aminotransferase increased13.03.04.011--
Asthma10.01.03.010; 22.03.01.002---
Blood aldosterone decreased13.10.09.007---
Burning sensation08.01.09.029; 17.02.06.001---
Chills08.01.09.001; 15.05.03.016--
Erythema23.03.06.001---
Haematoma24.07.01.001--
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Injection site irritation08.02.03.027; 12.07.03.027---
Lacrimation increased06.08.02.004--
Nausea07.01.07.001--
Osteoporosis14.04.04.002; 15.02.03.002--
Pain08.01.08.004--
Priapism21.03.01.005; 24.04.12.007---
Prinzmetal angina02.02.02.019; 24.04.04.015---
Pyrexia08.05.02.003--
Retroperitoneal haemorrhage07.07.02.002; 12.01.17.018; 24.07.01.017--
Rhinitis11.01.13.004; 22.07.03.006--
Shock24.06.02.002---
Skin irritation23.03.04.009---
Skin necrosis23.03.03.011---
Thrombocytopenia01.08.01.002---
Thrombosis24.01.01.006---
Ulcer08.03.06.001---
The 1th Page    1 2    Next   Last    Total 2 Pages